Made for the UK. Informed by evidence.Our editorial promise
INTERNATIONAL CONTEXT FOR UK READERS

Obesity care in Asia

This collection gives UK readers context on India, Japan and the United Arab Emirates. It separates who may prescribe, which indication is authorised and what an insurer will fund. These national rules cannot be carried across to UK care, even when a medicine has the same ingredient or brand name.

Translate the rules, not just the brand name

Japan's optimal-use requirements and India's specialist-prescribing conditions cannot be replaced by eligibility wording from a UK clinic. Ask the local clinician to identify the rule that applies to your proposed treatment.

Registration is one step

A regulator's approval of a new formulation establishes its regulatory status. It does not confirm its launch date, continuous stock, insurance acceptance or the total charge for treatment and follow-up.

Explore the country guides

3 guides

India ↗

India's central approval records and 2026 prescribing communications are more useful than launch advertising for establishing access. The exact product, approved indication and permitted prescriber all matter when comparing an offer.

Read the country guide →

Japan ↗

Japan's obesity-treatment pathway includes optimal-use guidance and requirements for the medical institution, as well as patient eligibility. A self-pay clinic offer should not be treated as evidence of access through public health insurance.

Read the country guide →

United Arab Emirates ↗

The Emirates Drug Establishment provides a national registered-product directory, while the patient's clinical service and insurer determine practical access and payment. A registration announcement should not be read as guaranteed pharmacy stock.

Read the country guide →